Website Search
ID 1016

Diagnosis, Targeted therapies: Targeting activators, Sawyer 4

Description:
Professor Charles Sawyer explains that EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S.
Transcript:
Charles Sawyer, M.D. is professor of medicine and director of the Prostate Cancer Program Area at U.C.L.A. Johnsson Comprehensive Cancer Center, and an investigator of the Howard Hughes Medical Institute. He works on therapies that target specific mutations in prostate cancer and chronic myeloid leukemia (CML). Here he describes his work developing a targeted therapy for CML patients with resistance to the anti-cancer drug Gleevec. “I think in a more general way, this is a paradigm for how we will do this with the whole range of kinase inhibitors that are not quite as fully developed as the Gleevec story, but are coming along. I think the next example will be lung cancer, for which the EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S. due to a mutation that was just recently described. In phase one study. The lung cancer patients in that study, a few of them had some benefit. That led to the decision empirically now to do a large study in lung cancer. And when that was done, about 10 percent of patients had miraculous types of responses. And the in other 90 percent nothing happened so that raises some conundrums for clinical development is obviously you would like to understand what was it about those 10 percent of patients.”
Keywords:
chronic myeloid leukemia, cancer drug gleevec, prostate cancer program, lung cancer patients, hughes medical institute, cml patients, egf receptor, prostate cancer, conundrums, lung cancer, phase one, gleevec, mutations, leukemia, mutation
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

1014. Diagnosis, Targeted therapies: Targeting activators, Sawyer 2
Professor Charles Sawyer explains that Gleevec is a pill taken once a day and works remarkably well in all phases of CML.
1012. Diagnosis, Targeted therapies: Targeting activators
In this section learn that tyrosine kinases are a family of activator proteins that trigger the cell signaling process leading to cell growth and division.
1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
1010. Diagnosis, Targeted therapies
Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.
1015. Diagnosis, Targeted therapies: Targeting activators, Sawyer 3
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15712. Bud and Yvonne
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
16109. Sense of urgency, Brian Druker
Brian Druker talks about sense of urgency.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving